alzheimer's disease

Displaying 58 studies

  • Dominantly Inherited Alzheimer Network (DIAN) Jacksonville, FL

    The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

  • A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease Jacksonville, FL

    The purpose of this study is to test whether two investigational drugs called CAD106 and CNP520, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.

  • Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD Rochester, MN

    The study is designed to assess the demographic, clinical and imaging associations with the presence of microbleeds in atypical Alzheimer's disease. The primary hypothesis is that cognitive and functional performance will be poorer in atypical Alzheimer's subjects with microbleeds compared to those without microbleeds.

  • Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo Jacksonville, FL

    To test the idea that solanezumab will slow the cognitive and functional decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.

  • Systolic Blood Pressure Intervention Trial: Alzheimer’s, Seniors, and Kidneys Jacksonville, FL

    There is evidence that high blood pressure can cause changes in memory and thinking as people get older. When the SPRINT study intervention was stopped in September of 2015, important data on long term rate of Alzheimer’s, change in cognition, and impact on the kidneys were not able to be collected. Participants from the SPRINT study will undergo a single SPRINT ASK visit approximately two years after their SPRINT closeout visit to assess blood pressure, cognitive and kidney function.

  • The Cognitive Effects of Lorazepam in Healthy Older Individuals with TOMM40 Variable-length Polymorphisms Scottsdale/Phoenix, AZ

    The investigators' goal is to determine if certain tests of memory and attention, performed while sleepiness is induced by a single dose of lorazepam, can predict whether or not an individual is at risk for developing Alzheimer's disease.

  • A Safety, Methodological and Exploratory Biomarkers Study to Slow Disease Progression Jacksonville, FL

    The purpose of this study is to determine safety of plasma infusion or exchange in APOE 44 patients.
     

  • A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease Scottsdale/Phoenix, AZ

    The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.

  • A Long Term Study of Molecular and Structural Imaging in Atypical Alzheimer's Disease Rochester, MN

    The purpose of this study is to learn more about amyloid and tau burden in the brain of patients with Atypical Alzheimer's Disease and how that burden may change over a two-year period.

  • A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease Scottsdale/Phoenix, AZ

    This randomized, placebo-controlled, double-blind, parallel-arm study will evaluate the safety and tolerability of at least two dose levels of intravenous (IV) crenezumab in 24-72 participants with mild to moderate Alzheimer disease (AD) (mini-mental state examination [MMSE] 18 to 28 points, inclusive). An optional open-label extension (OLE) will be offered after the completion of initial double-blind stage.

  • A Study to Evaluate Alzheimer Disease Biomarkers in Cerebrospinal Fluid (CSF) Rochester, MN

    The purpose of this study is to validate the Alzheimer Disease Biomarkers assays (Phospho-Tau/Total-Tau/Ab42) being implemented at Mayo to compare them to the referral tests in support of test validation efforts.

  • A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease Scottsdale/Phoenix, AZ

    The purpose of this study is to test whether two investigational drugs called CAD106 and CNP520, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.

  • A Study for Long Term Evaluation of Amyloid Risk and Neurodegeneration Jacksonville, FL; Rochester, MN

    The purpose of this study is to evaluate the rate of cognitive change in clinically normal older individuals who "screen-failed" for the A4 trial on the basis of their screening PET imaging not demonstrating evidence of elevated amyloid accumulation ( were Aβ negative) but met all other A4 study eligibility criteria. While long term data suggests that older individuals with elevated Aβ burden are at increased risk of cognitive decline, it is important to demonstrate the different rate of clinical decline between Aβe ("Aβ elevated") and Aβne ("Aβ not elevated") individuals.  

  • Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study Jacksonville, FL

    5.4 million Americans have Alzheimer's disease (AD) costing $185 billion annually, while 15 million caregivers look after these individuals. AD is the sixth leading cause of death, but the only one in the top 10 causes that cannot be prevented.

    This study may demonstrate exercise in an amount attainable by many will be preventative in asymptomatic individuals including those with brain Abeta deposition already that are at impending risk of the disease. Sperling and colleagues(1) coined the research term AD-pathophysiological process (abbreviated AD-P) for use in studies such as the intervention in this proposal.

    Our long term goal is to assess whether ...

  • The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF) Jacksonville, FL; Rochester, MN

    An urgent need exists to find effective treatments for Alzheimer's disease (AD) that can arrest or reverse the disease at its earliest stages. The emotional and financial burden of AD to patients, family members, and society is enormous, and is predicted to grow exponentially as the median population age increases. Current FDA-approved therapies are modestly effective at best. This study will examine a novel therapeutic approach using intranasal insulin (INI) that has shown promise in short-term clinical trials. If successful, information gained from the study has the potential to move INI forward rapidly as a therapy for AD. The study ...

  • Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss Jacksonville, FL; Rochester, MN

    The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease [AD]).

  • Effects of Aging and Aerobic Exercise Training on Brain Glucose Metabolism Rochester, MN

    Aging is associated with a loss of brain function and conditions such as dementia and Alzheimer's disease. It is likely that decreased brain metabolism is contributing to the progression of age related degenerative diseases. Aerobic exercise training can increase brain volumes and is associated with decreased risk for degenerative brain conditions. However, little is know about the changes that occur to brain metabolism with aerobic training and aging.

  • A Study to Evaluate Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease Rochester, MN

    The purpose of this study is to investigate how abrupt loss of ovarian hormones following bilateral oophorectomy affects overall aging, physical performance, and cognitive function, including the risk for Alzheimer’s disease in women who had this procedure performed prior to natural menopause for benign conditions.

  • A Study of the Effectiveness of LY3314814 in Patients with Mild Alzheimer's Disease Dementia Jacksonville, FL

    The purpose of this study is to evaluate the effectiveness of LY3314814 in the treatment of people who have mild Alzheimer's disease dementia.

  • An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738) Scottsdale/Phoenix, AZ

    This study consists of two parts, Part I and Part II. The purpose of Part I of the study is to assess the efficacy and safety of MK-8931 compared with placebo administered for 78 weeks in the treatment of Alzheimer's Disease (AD). The primary study hypotheses for Part I are that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) score and that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change ...

  • An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD) Jacksonville, FL

    The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in subjects with early Alzheimer's disease (AD).

  • 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease Jacksonville, FL

    The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD. Secondary objectives are to assess the effect of monthly doses of aducanumab as compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE), AD Assessment Scale-Cognitive Subscale (13 items) [ADAS-Cog 13], and AD Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version) [ADCS-ADL-MCI].

  • An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia Jacksonville, FL

    The purpose of this study is to evaluate whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants who are asymptomatic at risk for developing Alzheimer's dementia.

  • A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients with Mild to Moderate Alzheimer's Disease Scottsdale/Phoenix, AZ

    The purpose of this study is to evaluate the safety and effectiveness of MABT5102A in patients who have mild to moderate Alzheimer's Disease.

  • A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease Jacksonville, FL

    The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.

  • Partnership for Early Detection of Alzheimer's Disease Using Advanced MR Technology Rochester, MN

    The primary objective of this application is to establish the feasibility of widespread clinical use of advanced MRS technology for early AD diagnosis in a strategic alliance between MR physicists at the UMN and physician scientists at Mayo Clinic.

  • Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID) Scottsdale/Phoenix, AZ

    A brain PET scan is recognized as "reasonable and necessary" for some patients with "a recently established diagnosis of dementia" (Centers for Medicare and Medicaid Services, Decision Memo CAG-00088R, 2004), but evidence is less clear for patients having less severe cognitive problems. A substantial portion of such patients will develop Alzheimer's disease and other forms of dementia, which affect millions of people in the U.S., costing us over $100 billion annually. This project employs a prospective randomized protocol to determine whether PET scanning can help distinguish those patients with early Alzheimer's changes in their brains from those having other causes ...

  • Evaluation of Retinal Imaging in Patients with Alzheimer’s Disease Rochester, MN

    The purpose of this study is to explore the various retinal modalities to determine if they may provide a non-invasive method of identifying populations at risk for developing Alzheimer’s Disease (AD) and predict disease progression.

  • A Study of the Safety and Effectiveness of Suvorexant (MK-4305) for the Treatment of Insomnia in People who have Alzheimer's Disease Rochester, MN

    The purpose of this study is to examine the safety and effectiveness of suvorexant (MK-4305) to improve sleep in individuals who have Alzheimer's disease.

  • A Study to Evaluate Intentional Technology Pairing for Caregivers of Patients with Alzheimer’s Disease and Other Types of Dementia Rochester, MN

    The purpose of this study is to facilitate focus groups to assess/identify important qualities and characteristics that dementia caregivers are looking for in a supportive person, and to design a prototype website for matching current and former caregivers.

  • Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline Scottsdale/Phoenix, AZ

    This study is designed to determine the effectiveness of florbetapir (18F) in changing patient management and to evaluate the association between scan status and cognitive decline.

  • 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease Rochester, MN

    The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD. Secondary objectives are to assess the effect of monthly doses of aducanumab as compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE), AD Assessment Scale-Cognitive Subscale (13 items) [ADAS-Cog 13], and AD Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version) [ADCS-ADL-MCI].

  • Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) Jacksonville, FL; Rochester, MN

    The purpose of this study is to provide subjects who have completed participation in a Phase 2 or Phase 3 trial with TRx0237 continued access to therapy and to evaluate the long-term safety of TRx0237.

  • A Study to Evaluate the Safety and Effectiveness of Gantenerumab in Participants With Early Alzheimer's Disease (AD) Scottsdale/Phoenix, AZ

    The purpose of this study is to evaluate the effectiveness and safety of gantenerumab versus placebo in participants with early (prodromal to mild) Alzheimer's Disease (AD). All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will be performed at the end of the double blind period at week 104. Participants will then be offered to enter into an open-label extension (OLE). Participants not willing to go to the OLE will participate in a long term follow-up period for up to 50 weeks ...

  • The Impact of Cognitive Impairment on Driving Safety. Rochester, MN

    Automobile driving is a crucial aspect of everyday life, but driving safety problems including car crashes or speeding violations are a serious public health problem. Alzheimer’s Disease (AD) affects the ability to safely drive and raises crash risk. Mild cognitive impairment (MCI) raises the risk of dementia, and people with MCI have been shown to have problems with memory, decision making, and the ability to concentrate that could lead to unsafe driving, even before obvious dementia begins. Whether MCI patients who continue to drive are safe drivers or not is unknown.

  • Advancing Reliable Measurement in Alzheimer's Disease and Cognitive Aging Jacksonville, FL

    This study seeks to validate and further develop the NIH Toolbox for Assessment of Neurological and Behavioral Function® (NIHTB) for use in studies of cognitive aging beginning with normal cognition through progression into amnestic Mild Cognitive Impairment (aMCI) and into dementia of the Alzheimer’s Type, early stage (DAT).

  • Bridging Study of C11 PiB and F18 Flutemetamol Brain PET Rochester, MN

    The intent of this research protocol is to test the equivalency of two amyloid imaging drugs (C11 Pittsburgh Compound B and F18 Flutemetamol). The investigators hypothesize that there will be no significant difference in the distribution of the agents to areas of amyloid deposition in the brain or to other normal brain structures. Recent data have shown similarity in the distribution of the drugs in subjects with AD or mild cognitive impairment (MCI). No comparison data of the two PET drugs in normal subjects has been published. It is important to understand differences in the images and biodistribution from the ...

  • Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol Jacksonville, FL; Rochester, MN

    Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.

  • Efficacy and Safety Trial of MK-8931 in Participants With Prodromal Alzheimer's Disease (MK-8931-019) Scottsdale/Phoenix, AZ

    The purpose of this trial is to assess the efficacy and safety of MK-8931 compared with placebo in the treatment of amnestic mild cognitive impairment (aMCI) due to Alzheimer's Disease (AD), also known as prodromal AD. Participants will be randomized to receive placebo, or 12 mg or 40 mg MK-8931, once daily. The primary study hypothesis is that at least one MK-8931 dose is superior to placebo with respect to the change from baseline in the Clinical Dementia Rating scale-Sum of Boxes (CDR-SB) score at 104 weeks.

  • PiB PET Scanning in Speech and Language Based Dementias Rochester, MN

    The study is designed to determine whether there are clinical features that can be used as biomarkers to predict whether underlying Alzheimer's pathology is the cause of a speech and language based dementia. The primary hypothesis is that the proportion of patients who test positive for beta-amyloid deposition will vary across different speech and language based dementias.

  • Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI and AD Subjects Scottsdale/Phoenix, AZ

    This is a cross-sectional and longitudinal study that will evaluate imaging characteristics of 18F-AV-1451 in cognitively healthy volunteers, mild cognitive impairment (MCI) and Alzheimer's disease (AD) subjects.

  • A Study Evaluating the Use of 48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer’s Disease Jacksonville, FL

    The purpose of this study is to characterize and study the relationship of the clinical risk factors and predictors of seizures and epilepsy in patients with Early Onset Alzheimer's Disease (EOAD) using a 48-hour CAA-EEG.

  • A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease Jacksonville, FL

    This study seeks to evaluate the efficacy and safety of ABBV-8E12 in subjects with Early Alzheimer's Disease.

  • DaTSCAN Imaging in Aging and Neurodegenerative Disease Rochester, MN

    The investigators propose using DaTscan in patients with mild cognitive impairment (MCI), Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease (AD), and other neurodegenerative syndromes and disorders, to test several hypotheses - some confirmatory, and some novel. Such use will provide new data on the potential clinical and research utility of DaTscan in neurodegenerative diseases. The findings on DaTscan will be correlated with clinical diagnoses and other multimodal imaging studies (e.g., MRI, MRS, FDG-PET, and amyloid-PET) to enhance our understanding of neurodegenerative diseases.

  • Parkinson's Disease iPS Cell Line Research Consortium Scottsdale/Phoenix, AZ; Jacksonville, FL

    This study is being done to collect skin samples from people with and without neurodegenerative and vascular disorders including Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), stroke and many others. We will use these skin samples to make and bank (store) a group of cells (cell line) called inducible pluripotent stem (iPS) cells.

  • A Study of Specialized Systems in the Brain and How They Relate to the Disease Processes in aMCI and AD Rochester, MN

    This study is being done to learn more about specialized systems in the brain and how they relate to the disease processes in aMCI and AD.

  • A Study to Collect Blood DNA Samples from Patients with Clinically Diagnosed Alzheimers Disease, Lewy Body Disease, and Frontotemporal Degeneration Rochester, MN

    The purpose of this study is to collect blood samples for DNA analysis from patients clinically diagnosed with Alzheimers disease, Lewy Body disease, and Frontotemporal degeneration.

  • Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) Scottsdale/Phoenix, AZ

    This study consists of two parts, Part I and Part II. The purpose of Part I of the study is to assess the efficacy and safety of verubecestat (MK-8931) compared with placebo administered for 104 weeks in the treatment of amnestic mild cognitive impairment (aMCI) due to Alzheimer's Disease (AD), also known as prodromal AD. Participants will be randomized to receive placebo, or 12 mg or 40 mg verubecestat, once daily. The primary study hypothesis for Part I is that at least one verubecestat dose is superior to placebo with respect to the change from baseline in the Clinical Dementia ...

  • Mayo Alzheimer's Disease Research Center Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN

    This study is being done to learn more about normal memory and aging, mild memory and thinking problems, Alzheimer's disease and other forms of dementia.

  • Magnetic Resonance Elastography of Dementia Rochester, MN

    The purpose of this study is to develop and test the effectiveness of an investigational imaging technique called magnetic resonance elastography (MRE) to measure the stiffness (mechanical properties) of tissues.

  • A Study of the Brain & Body Donation Program Scottsdale/Phoenix, AZ

    The purpose of this study is to study the structure and biochemistry of the brain and/or bodily fluid and tissue after death.  Comparison of specimens from normal and diseased individuals provide essential clues that lead to a greater understanding of the diseased state which, in turn, will lead to new ideas for therapy.

  • A Study to Evaluate MR of CSF Dynamics Rochester, MN

    The purpose of this study is to evaluate changes in CSF dynamics (e.g., velocity, flow rate) between patients with normal pressure hydrocephalus and healthy controls, as well as patients with other dementia disorders.

  • Mayo Clinic Olmsted Study of Aging (MCSA) Rochester, MN

    This study is being done to learn more about normal memory and aging, mild memory and thinking problems, Alzheimer's disease and other forms of dementia. This study will help us determine how often memory problems occur in people in our community, and help to identify factors that may influence changes in memory and thinking skills.

  • Cerebrospinal Fluid (CSF) Biomarkers for Prediction of Dementia Jacksonville, FL; Rochester, MN

    To further investigate biomarkers in CSF as possible predictors for mild cognitive impairment and dementia

  • Cross-sectional, Multinational, Noninterventional Study to Evaluate the Psychometric Comparability of Culturally Adapted Versions of the Global Preclinical Alzheimer’s Cognitive Composite (G-PACC) Jacksonville, FL

    The main goal of this study is to evaluate whether a certain set of memory and thinking tests that are in English also work in other languages after they are translated. The measures will test your memory, thinking, problem solving, and everyday function abilities.

  • A Study of Early-onset Alzheimer's Disease Jacksonville, FL; Rochester, MN

    The purpose of this Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is designed to look at disease progression in individuals with early onset cognitive impairment . Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EO-nonAD) participants,and (3) cognitively normal (CN) control participants.

  • Advanced Care Planning in Dementia Jacksonville, FL

    The goal of this study is to gain a better understanding of the status of advanced care planning among caregivers of patients with dementia and examine how this differs by race and disease stage.

  • A Study to Assess Educational Needs and Perceived Barriers to Care Among Individuals with Chronic Health Conditions and Their Caregivers Jacksonville, FL; Rochester, MN

    The purpose of this study is to assess educational needs and barriers to care in both patients with cancer and other serious chronic conditions, as well as their caregivers.

.

Mayo Clinic Footer